2-(2-Methylbenzoyl)cyclohexanone | 7402-38-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Methylbenzoyl)cyclohexanone
• 英文别名: 2-(2-methylbenzoyl)cyclohexan-1-one
• CAS: 7402-38-2
• 化学式: C₁₄H₁₆O₂
• 分子量: 216.27
• InChiKey: NEDBCLWQCXIEJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-Methylbenzoyl)cyclohexanone 以44%的产率得到
  参考文献：
  名称：

  HORNBACK, JOSEPH M.;POUNDSTONE, MELANI L.;VADLAMANI, BHANUMATHI;GRAHAM, S+, J. ORG. CHEM., 53,(1988) N4, C. 5508-5601

  摘要：

  DOI：
• 作为产物：
  描述：

  (2Z)-2-[(tert-butylamino)-(2-methylphenyl)methylidene]cyclohexan-1-one 、 盐酸 以85%的产率得到
  参考文献：
  名称：

  BAUDOUX, D.;FUKS, R., BULL. SOC. CHIM. BELG., 1984, 93, N 11, 1009-1017

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY<br/>[FR] DERIVES D'ACIDES ARYLALCANOIQUES SUBSTITUES SERVANT D'AGONISTES DE PPAR PAN AYANT UNE FORTE ACTIVITE ANTIHYPERGLYCEMIQUE ET ANTIHYPERLIPIDEMIQUE
  申请人：SHENZHEN CHIPSCREEN BIOSCIENCE

  公开号：WO2004048333A1

  公开（公告）日：2004-06-10

  Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, Rl, R2, R3, R4, R5, X, Alkl, Alk2, Arl, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXRJPPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

  本文披露了按照公式I的替代芳基脂肪酸衍生物的制备和药用，其中环A、环B、R1、R2、R3、R4、R5、X、Alkl、Alk2、Arl和Ar2如规范中定义。这些化合物作为选择性激动剂，激活过氧化物酶体增殖物激活受体（PPAR），特别是RXR/PPARα、RXR/PPARγ和RXR/PPARδ异源二聚体，在治疗和/或预防2型糖尿病及相关代谢综合征（如高血压、肥胖、胰岛素抵抗、高脂血症、高血糖、高胆固醇血症、动脉粥样硬化、冠状动脉疾病等）方面具有用处，且常规PPARγ激动剂常见的副作用改善。
• Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
  申请人：——

  公开号：US20040142921A1

  公开（公告）日：2004-07-22

  Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , X, Alk 1 , Alk 2 , Ar 1 , and Ar 2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists. 1

  本发明涉及I式取代芳基脂肪酸衍生物的制备和药用，其中环A、环B、R1、R2、R3、R4、R5、X、Alk1、Alk2、Ar1和Ar2如规范中所定义。这些化合物作为选择性激动剂激活过氧化物酶体增殖物激活受体（PPAR），特别是RXR/PPARα、RXR/PPARγ和RXR/PPARδ异二聚体，在治疗和/或预防2型糖尿病和相关代谢综合征方面非常有用，例如高血压、肥胖、胰岛素抵抗、高脂血症、高血糖、高胆固醇血症、动脉粥样硬化、冠状动脉疾病和其他心血管疾病，且具有改善副作用剖面的优点，通常与传统的PPARγ激动剂有关。
• Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
  申请人：Lu Xian-Ping

  公开号：US20080051321A1

  公开（公告）日：2008-02-28

  Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , X, Alk 1 , Alk 2 , Ar 1 , and Ar 2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

  本发明涉及一种Formula I的取代芳基脂肪酸衍生物的制备和药用，其中环A、环B、R1、R2、R3、R4、R5、X、Alk1、Alk2、Ar1和Ar2如规范中所定义。这些化合物作为选择性激动剂激活过氧化物酶体增殖物激活受体（PPAR），特别是RXR / PPARalpha，RXR / PPARgamma和RXR / PPARdelta异二聚体，在治疗和/或预防2型糖尿病和相关代谢综合症，如高血压、肥胖症、胰岛素抵抗、高脂血症、高血糖、高胆固醇血症、动脉粥样硬化、冠状动脉疾病和其他心血管疾病方面具有改善常见的PPARgamma激动剂副作用剖面。
• HORNBACK, JOSEPH M.;POUNDSTONE, MELANI L.;VADLAMANI, BHANUMATHI;GRAHAM, S+, J. ORG. CHEM., 53,(1988) N4, C. 5508-5601
  作者：HORNBACK, JOSEPH M.、POUNDSTONE, MELANI L.、VADLAMANI, BHANUMATHI、GRAHAM, S+

  DOI：——

  日期：——
• EP1569904A4
  申请人：——

  公开号：EP1569904A4

  公开（公告）日：2008-04-16